The variation in Hb increases by treatment purpose—highest in HF patients (1.3 g/dL), followed by DM (1.0 g/dL) and CKD (0.9 g/dL)—suggests that underlying disease states modulate the hematologic response. Here, GSTM1 is linked to diabetes mellitus.